Competition from Novartis
Novartis is also in the process of developing a CAR-T therapy, which is scheduled to make it to market before Kite's product. It also won an FDA panel's unanimous backing, which speaks to the power behind the upcoming therapy. Their applications differ, but Novartis' pricing will surely affect what those will find fair to pay for axicabtagene ciloleucel. Novartis CEO appears to be working toward a fair pricing strategy for consumers, as he has invited fair pricing activists to work alongside him in developing a cost. The drugs are expensive to manufacture, making it a difficult solution to find.